Staying Ahead of EFGR Dermatological Toxicities in CRC

Epidermal growth factor receptor (EGFR) inhibitors such as panitumumab are pivotal in treating metastatic colorectal cancer (mCRC) patients with wild-type KRAS mutations in the first, second and third lines, especially in patients with wild-type RAS genes.

‘Tip of the spear’

Throughout my military career, I would hear the phrase ‘tip of the spear’ to describe units or leaders who were first to the fight. The metaphor refers to the business end of one of the oldest weapons of warfare, the spear. As Madeline Miller in “The Song of Achilles” says, “You can use a spear as a walking stick, but that will not change its nature.” Everyone understands what the spear represents and what it is for. As military medical physicians, we often discuss our role as the “soft side of the spear.” We were not at the pointy end, but we certainly supported the effective implementation and application of force embodied by the spear tip.

Soft-Tissue Sarcoma Rates Higher in Middle-Aged Servicemembers

While the incidence rates of soft-tissue sarcomas are lower in young U.S. active-duty military servicemen compared with those in the general population, according to a new study, those are higher in middle-aged servicemen, possibly because of greater cumulative exposure to toxins.

Clotrimazole Shows Promise in Improving NSCLC Survival

Preclinical data has suggested antifungal azole derivatives have antitumor efficacy that might modulate response to immune checkpoint inhibitors (ICIs). A new study evaluated the association of azole drugs with overall survival (OS) in a population of patients with non-small cell lung cancer (NSCLC) treated with ICI within the VHA.

Multiple Comorbidities Affect NSCLC Survival in Older Veterans

Most advanced non-small cell lung cancer (NSCLC) patients are older adults, and they often have multiple other comorbidities (multimorbidity) when initiating treatment. A new study sought to learn more about the nature and impact of multimorbidity, especially since aging patients are often excluded from clinical trials.